Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers August 22, 2017
Pharmacy Choice - News - U.S. Pharmaceutical Industry - August 22, 2017

Pharmacy News

 U.S. Pharmaceutical Industry
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

8/22/17 - AEPP Announces Proposed Name Change to Oncolix, Inc.
AEPP, a Houston- based biotechnology company focused on gynecological cancers, today announced it intends to change its name to Oncolix, Inc. The new name is expected to be effective after the mailing of notice to its shareholders in September. AEPP recently acquired all of the outstanding securities of Oncolix, Inc. in a reverse merger completed
8/22/17 - Agile Therapeutics to Present at the Rodman & Renshaw 19th Annual Global Investment Conference
Agile Therapeutics, Inc. a women s health specialty pharmaceutical company, announced today that Al Altomari, Chairman and CEO will present at the Rodman& Renshaw 19 th Annual Global Investment Conference on Tuesday, September 12, 2017 at 9:10 AM ET in New York.. To access the live and archived webcasts of the presentation, visit the Investor
8/22/17 - Albireo Reports Second Quarter 2017 Financial Results
Release date- 21082017- BOSTON- Albireo Pharma, Inc., a clinical stage orphan pediatric liver disease company developing novel bile acid modulators, today reported its financial results for the second quarter and six months ended June 30, 2017 and provided a business update. For the six months ended June 30, 2017, Albireo reported a net loss of $12
8/22/17 - ALK to accelerate launches of ODACTRA in the USA / ACARIZAX in Canada [T-break Tech (Middle East)]
The FDA has today transferred the US product licences for the SLIT-tablet portfolio to ALK allowing the company to give full speed on the US activities. ALK plans to expand pivotal Phase III clinical trial on allergic asthma to include US patients based on discussions with the FDA. Full-year financial guidance for operating profit has been revised
8/22/17 - Alkermes Initiates Rolling Submission of ALKS 5461 New Drug Application for Major Depressive Disorder
Release date- 21082017- DUBLIN- Alkermes plc today announced the initiation of its rolling submission of a New Drug Application to the U.S. Food and Drug Administration, seeking marketing approval of ALKS 5461, a once daily, oral investigational medicine with a novel mechanism of action, for the adjunctive treatment of major depressive disorder.
8/22/17 - Alliance Foundation Trials Opens Global Trial Investigating First-in-Class Palbociclib in HR+, HER2+ Metastatic Breast Cancer
The Alliance Foundation Trials, LLC, in conjunction with Pfizer and six international cancer research groups, today announced the launch of PATINA a randomized, open-label, Phase 3 clinical study of the cyclin-dependent kinase 4/ 6 inhibitor palbociclib. The PATINA trial offers an exciting opportunity for a new global collaborative initiative
8/22/17 - ALTIMMUNE SUBMITS INVESTIGATIONAL NEW DRUG APPLICATION FOR NASOVAX IN PREPARATION FOR PHASE 2 TRIAL
Release date- 21082017- GAITHERSBURG, Md.- Altimmune, Inc., a clinical-stage immunotherapeutics company, today announced the Company has submitted an Investigational New Drug application to the U.S Food and Drug Administration for NasoVAX, the Company's intranasally administered recombinant flu vaccine. Sybil Tasker, Chief Medical Officer at Altimm
8/22/17 - American Lung Association Names 2017-2018 Volunteer Spokespeople
The American Lung Association issued the following news release:. Serving as the nation's premiere resource for lung health, the American Lung Association has expanded its network of expert resources available to the news media through the fiscal year 2018 National Volunteer Spokesperson program. The American Lung Association's 2017-2018 volunteer.
8/22/17 - Antimicrobial Coatings Market to Gain From Increasing Need of Hygiene in Various Industries From 2014 to 2025: Million Insights
The global antimicrobial coating market was worth USD 2.44 billion in 2015. Indian pharmaceutical companies are driving into antimicrobial market to be in line with the regulatory standards. The effect of micro-organisms on people improves health concerns owing to boost the market over the forecast period.
8/22/17 - APNewsBreak: Utah to obey order for DEA drug database search
Utah will obey a court order to let the U.S. Drug Enforcement Administration search a prescription-drug database without a warrant, despite a state law designed to protect patient privacy. A federal appeals court also sided with the DEA in a case involving subpoenas of Oregon's prescription-drug database. The DEA fought to be exempt from the law
8/22/17 - Astellas Pharma Inc. - First Patient Dosed in Phase 3 MORPHO Trial Evaluating Gilteritinib as Maintenance Therapy
Release date- 21082017- TOKYO- Astellas Pharma Inc. announced today that the first patient was dosed in the registrational Phase 3 MORPHO trial of gilteritinib, the fourth Phase 3 trial underway in the gilteritinib clinical development program. 'We know that FLT3+ AML patients face potentially worse outcomes than those with other mutations, and whi
8/22/17 - Atara Biotherapeutics Expands Leadership Team with the Appointment of Dr. Kanya Rajangam as Senior Vice President and Chief Medical Officer
Atara Biotherapeutics, Inc., a leading "off-the-shelf" T-cell immunotherapy company developing novel treatments for patients with cancer and multiple sclerosis, today announced the appointment of Kanya Rajangam, M.D., Ph.D., as Senior Vice President and Chief Medical Officer. Kanya has an exemplary track record leading clinical development and
8/22/17 - B. Braun Launches New Dialyzer
B. Braun Medical issued the following news release:. B. Braun Medical Inc. today announced that the U.S. Food and Drug Administration has cleared its hemodialyzer, Diacap (R) Pro. "The newly developed fibers in Diacap Pro are designed to improve dialysis dose," said Samuel Amory, Vice President at B. Braun Medical.
8/22/17 - BCC to Enter Into Joint Venture With Israeli Pharmaceutical Company Panaxia
The Canadian Bioceutical Corporation today announced the signing of a Term Sheet outlining the binding conditions under which it will enter into a Joint Venture agreement with Panaxia Pharmaceutical Industries Ltd.. Under the terms of the agreement, Panaxia will be providing proprietary, smokeless, pharma-grade cannabis-based products that have b
8/22/17 - Bio Pharma Buffer 2017 Global Market Outlook,Research,Trends and Forecast to 2022
This report studies the Bio Pharma Buffer market status and outlook of global and United States, from angles of players, regions, product types and end industries; this report analyzes the top players in global and United States market, and splits the Bio Pharma Buffer market by product type and applications/end industries. The Asia-Pacific will oc
8/22/17 - BUYINS.NET: BUYINS.NET: CVS SqueezeTrigger Price is $77.87. There is $2,014,110,743 That Short Sellers Still Need To Cover.
BUYINS.NET/ www.buyins.net is monitoring CVS Caremark Corp in real time and just received an alert that CVS is crossing above its primary SqueezeTrigger Price, the price that a short squeeze can start in any stock. There are 3,052,945,503 shares that have been shorted at the volume weighted average SqueezeTrigger Price of $77.87. From August 2012 t
8/22/17 - BUYINS.NET: CVS SqueezeTrigger Price is $77.87. There is $2,014,110,743 That Short Sellers Still Need To Cover.
August 22, 2017 / M2 PRESSWIRE / BUYINS.NET / www.buyins.net is monitoring CVS Caremark Corp (NYSE:CVS) in real time and just received an alert that CVS is crossing above its primary SqueezeTrigger Price, the price that a short squeeze can start in a...
8/22/17 - Cardiome Provides U.S. Regulatory Update for BRINAVESS
Release date- 21082017- Vancouver, Canada- Cardiome Pharma Corp. today announced that it has received a response from the U.S. Food and Drug Administration regarding the regulatory path for BRINAVESS, the Company's antiarrhythmic drug for the rapid conversion of recent onset atrial fibrillation. 'In our most recent communication with the FDA, we pr
8/22/17 - Cellectar Biosciences Announces Significant PDC Platform Advancement; Demonstrates Potential to Improve Therapeutic Window
Cellectar Biosciences, Inc., an oncology-focused, clinical stage biotechnology company, today announces that its Phospholipid Drug Conjugate research program has generated numerous PDC molecules that show significant improved pharmacologic activity versus the payload molecule alone.. Utilizing a selection of novel linkers to attach proprietary...
8/22/17 - Celularity, Inc., Accelerates Breakthrough Placental Discovery & Therapeutic Platform [India Infoline News Service]
Celularity, Inc., Accelerates Breakthrough Placental Discovery& Therapeutic Platform Business Wire India. Celularity completed their Series A financing with contributions from several biopharma companies, including Sorrento Therapeutics, United Therapeutics Corporation and Human Longevity, Inc., and entrepreneurial investors.
8/22/17 - Clementia Announces Closing of Over - Allotment Option in its Initial Public Offering
Release date- 21082017- MONTREAL- Clementia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, today announced that the underwriters of its previously announced initial public offering exercised their option to purchase an additional 1,191,000 common shares from Clementia at the public offering price of $15.00 per share, resulting in
8/22/17 - Clementia Announces Closing of Over-Allotment Option in its Initial Public Offering [Syrian Arab News Agency]
Clementia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, today announced that the underwriters of its previously announced initial public offering exercised their option to purchase an additional 1,191,000 common shares from Clementia at the public offering price of $15.00 per share, resulting in additional gross proceeds of...
8/22/17 - Clinical and Regulatory Progress Boosting Biotech Sector
Advancing biotechs this week include: Moleculin Biotech, Inc.,, Pfizer Inc., Merck& Co., AVEO Pharmaceuticals Inc., Sucampo Pharmaceuticals Inc.. Moleculin Biotech, Inc.,, a preclinical pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on license agreements with The University of Texas System
8/22/17 - Contract Research Organizations (CROs) Services Global Market 2017 Share, Trend, Segmentation and Forecast to 2022
PUNE, INDIA, August 22, 2017/ EINPresswire.com/ Global Contract Research Organizations Services Market This report mainly introduces volume and value market share by players, by regions, by product type, by consumers and also their price change details. As a Detailed Analysis report, it covers all details inside analysis and opinion in Contract R
8/22/17 - ContraVir Pharmaceuticals Announces Issuance of New US Patent for Expansion of Cyclophilin Inhibitor Program
Release date- 21082017- EDISON, N.J.- ContraVir Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that the United States Patent and Trademark Office has issued a new patent, US 9,714,271 covering a broad collection of cyclophilin inhibitors.
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
RxSchool
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415